Gameto Highlights ARPA-H–Backed Menopause Program Ahead of ASRM 2025

Gameto has shared an update. The company announced that its R&D Chief of Staff, Alexander Noblett, PhD, will deliver a booth talk at ASRM 2025 titled “Reimagining Menopause Treatment with a Steroidogenic, Hormone-Sensitive Ovarian Implant.” The session will focus on Gameto’s Ameno program, which leverages engineered ovarian-like cells and controlled androgen release to develop a novel approach to menopause treatment. The Ameno program previously received funding from the Advanced Research Projects Agency for Health (ARPA-H) under its Sprint for Women’s Health Initiative in fall 2024.

For investors, this update highlights continued validation and visibility for Gameto’s technology platform in a large, underserved women’s health market. The prior ARPA-H funding signals external, non-dilutive support and scientific interest, which may help de-risk aspects of the R&D pipeline and strengthen the company’s position when seeking future partnerships or funding. The ASRM 2025 presence and scientific engagement could enhance Gameto’s reputation among clinicians and researchers, potentially accelerating clinical adoption and partnership opportunities if the Ameno program advances successfully. However, the announcement remains primarily scientific and promotional in nature and does not provide new data, regulatory milestones, or commercial timelines, so the immediate financial impact is limited and contingent on future clinical and regulatory progress.